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Purpose/Objective: EBRT remains one of the key treatment options in 
head and neck cancer (HNC). IMRT offers many advantages over 
3DCRT through the steep dose gradient providing decreased toxicity 
without compromising local control, especially in complex shaped 
target volumes such as those in HNC. IMRT, however increases the 
number of beams and monitor units delivered, resulting in an increase 
in treatment delivery time and patient exposure to low-dose 
irradiation. VMAT has been proposed as a treatment technique that 
can improve delivery efficiency when compared to IMRT while 
maintaining similar treatment plan quality and this concept has led to 
investigations into which technique is superior. The aim of this critical 
review of the literature was to compare and evaluate the superiority 
or otherwise of VMAT over IMRT in terms of plan quality and delivery 
efficiency for HNC.  
Materials and Methods: A critical review of published retrospective 
and prospective treatment planning comparison studies looking at 
IMRT and VMAT plans for HNC patients was completed. The review 
compared and evaluated homogeneity, coverage and conformity of 
the dose within the PTV, the dose to the OARs, the number of monitor 
units, the integral dose and the treatment delivery time for both 
techniques. A similar comparison was made between single arc (SA) 
and double arc (DA) VMAT to determine superiority.  
Results: All DA VMAT plans offered equivalent or superior dose 
coverage, homogeneity and conformity within the PTV and dose to the 
OARs, with the exception of nasopharyngeal and paranasal sinus 
disease sites. VMAT plans required fewer monitor units and less 
treatment delivery time in all studies when compared to IMRT.  
Conclusions: This critical review of the literature has shown IMRT and 
VMAT to be comparable techniques with the superiority of one over 
the other depending on the complexity of the target HNC volume. 
VMAT requires fewer monitor units which could potentially decrease 
the risk of secondary malignancies. VMAT also offers significantly 
reduced treatment delivery time, thus reducing the timeframe for 
intra-fraction motion and providing an opportunity for increased 
patient throughput in the radiation therapy department. 
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Purpose/Objective: The aim of this study was to compare the 
dosimetric characteristics of Tomotherapy (TOMO) and RapidArc (RA) 
for single intracranial lesion to assess which technique was more 
beneficial for intracranial radiosurgery treatments. 
Materials and Methods: Eleven patients presented with single brain 
lesion had completed Tomotherapy treatment. CT data sets were re-
planned using single-arc RA. Quantitative measurements of dose-
endpoint values on the dose-volume histograms were carried out for 
evaluation of dose homogeneity (Homogeneity Index (HI): D5% - D95%), 
degree of conformity (conformation number (CN)) and percentage 
volume of non-target brain tissue receiving 12Gy (V12, non-target brain tissue). 
Statistical analysis was done for the results. 
Results: RA and Tomotherapy plans had comparable dose conformity 
in planning target volumes (PTVs) (p=0.70). However, Tomotherapy 
plans achieved significantly better dose homogeneity (p=0.049). Mean 
percentage volume of non-target brain tissue received 12Gy was 
higher in Tomotherapy plans than in RA plans (p=0.18). 
 
Conclusions: From the results, Tomotherapy plans achieved superior 
target dose homogeneity. RA plans showed comparable dose 
conformity in PTVs. In general, RA plans yielded lower mean 
percentage volume of non-target brain tissue which received 12Gy. It 
might imply that a smaller late complication probability of the brain 
will result in RA plans. However, further studies are needed. To 
conclude, both Tomotherapy and RA were considered clinically 
acceptable for radiosurgery treatments.  
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Purpose/Objective: Radical radiotherapy has shown to be an effective 
method of treating localised prostate cancer. Randomized controlled 
trials have confirmed improved outcomes with dose escalation. In a 
small (but increasing) group of patients with metallic hip prosthesis, 
achieving dose escalation with conventional conformal planning is 
seldom possible without considerable morbidity due to unpredictable 
scatter and attenuation caused by the prosthesis. Recent advances 
with IMRT and the use of RapidArcTM (The VMAT solution provided by 
Varian as part of the EclipseTM treatment planning system) has 
provided a way of dose escalation in these patients. 
Materials and Methods: A retrospective audit was undertaken on 23 
consecutive patients with hip prosthesis treated with radiotherapy to 
the prostate using RapidArcTM at a UK Cancer Centre between April 
2009 and February 2011. Baseline characteristics, treatment details, 
adherence to dose constraints and toxicity were collected from 
patient records and radiotherapy plans. All RapidArcTM plans included 
avoidance sectors to prevent any beams entering through the 
prosthesis and consequently minimise any dose distribution 
uncertainties caused by the high density prosthesis. Optimization 
objectives were chosen to minimise doses to the rectum, bowel, 
bladder, and femoral heads, while keeping adequate PTV dose 
coverage. 
Results: 23 patients were audited, median age was 76 years and the 
median PSA was 8.9 ng/ml. 12 patients had unilateral and 11 had 
bilateral metallic hip prosthesis. 35% of patients had a high grade 
cancer (Gleason Grade >8), 52% had intermediate grade (Gleason 
Grade 7) and 13% had low grade cancers. 52% had organ confined 
cancer (T1&T2) and 48% had extra capsular spread (T3). 82% had 
neoadjuvant hormones with a median treatment duration of 3 months 
and 70% had both neoadjuvant and adjuvant hormones. All patients 
were planned with CT-MRI fusion and treated with RapidArcTM plans. 4 
patients were treated with two 360° arcs (CR 30° and 330°) and the 
rest had single 360° arc (CR 30°) plans. 96% of patients were treated 
with a dose of 72Gy/32#/44 days. 22% had prostate and pelvic lymph 
node radiotherapy (72Gy to Prostate & 50.4Gy to pelvic nodes in 32 
fractions concomitantly). 20 out of 23 plans met all constraints 
(Rectum, bladder and small bowel). 2 plans deviated from rectal 
constraints and 1 from bladder constraint; all 3 were classed as minor 
deviations. No grade 3 or 4 bowel and bladder toxicity was recorded.  
Conclusions: IMRT with RapidArcTM provides a safe and effective way 
of dose escalation in patients with unilateral and bilateral hip 
replacements. We plan to continue data collection on PSA control and 
long-term results. 
   
 
 
 
 
